Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.32 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.32 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL211495 | 0.93 | ADORA2B (0.33) | PRMT6ADORA2BADORA2AP2RY12ADORA3 | |
| SCHEMBL210112 | 0.93 | ADORA2B (0.33) | PRMT6ADORA2BADORA2AP2RY12ADORA3 | |
| SCHEMBL5558224 | 0.89 | TYMP (0.34) | PRMT6ADORA2BADORA2AP2RY12ADORA3 | |
| SCHEMBL1096766 | 0.89 | TYMP (0.34) | PRMT6ADORA2BADORA2AP2RY12ADORA3 | |
| SCHEMBL29881527 | 0.89 | TYMP (0.34) | PRMT6ADORA2BADORA2AP2RY12ADORA3 | |
| SCHEMBL19814045 | 0.88 | PRMT6 (0.33) | PRMT6ADORA2BADORA2AP2RY12ADORA3 | |
| SCHEMBL19825361 | 0.88 | PRMT6 (0.33) | PRMT6ADORA2BADORA2AP2RY12ADORA3 | |
| SCHEMBL211959 | 0.86 | ADORA2A (0.32) | PRMT6ADORA2BADORA2AP2RY12ADORA3 | |
| SCHEMBL19566538 | 0.86 | PRMT6 (0.37) | PRMT6ADORA2BADORA2AP2RY12ADORA1 | |
| SCHEMBL25727 | 0.86 | TYMP (0.33) | PRMT6ADORA2BADORA2AP2RY12PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703728-B2 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | ISIS PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20050059066-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | IONIS PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059066-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | OGG1, UNG, PCNA | PRMT6 4128/4885ADORA2B 3328/4885ADORA2A 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.